Plasma lipids affect maximum velocity not sodium affinity of human sodium-lithium countertransport: distinction from essential hypertension.
Inheritance is a major determinant of increased sodium-lithium countertransport (SLC) activity in hypertension. However, hyperlipidaemia can also cause increased SLC activity in some individuals and it is difficult to distinguish this effect from the effect of hypertension. Erythrocyte SLC activity and its kinetic determinants sodium affinity (km) and maximum velocity (Vmax) were measured in 25 hyperlipidaemic patients and 15 normal controls (NC). Increased SLC activity (0.31 +/- SEM 0.03 mmol Li/(h x 1 cells) vs. NC 0.20 +/- 0.01, P < 0.01) in the hyperlipidaemic patients was associated with increased Vmax (0.59 +/- 0.07 vs. NC 0.41 +/- 0.03, P < 0.01) but normal km (median 120 range [40-324] mmol l-1 vs. 140 [108-260]. Lipid-lowering therapy resulted in decreased SLC activity secondary to a fall in Vmax. Km remained constant despite the changes in lipids and Vmax. The mechanism of increased SLC activity in hyperlipidaemia is different from that in essential hypertension where increased sodium affinity is found. Measurement of the kinetic characteristics of SLC may discriminate between the independent influences of hypertension and hyperlipidaemia on the sodium-lithium countertransporter.
Rutherford
P A
PA
Department of Medicine, (Nephrology), Freeman Hospital, Newcastle upon Tyne, UK.
Thomas
T H
TH
Laker
M F
MF
Wilkinson
R
R
D000328:Adult; D017920:Antiporters; D002352:Carrier Proteins / Q000097:blood* / Q000235:genetics; D004912:Erythrocytes / Q000378:metabolism; D005260:Female; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood* / Q000188:drug therapy / Q000235:genetics; D006973:Hypertension / Q000097:blood / Q000235:genetics; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D017136:Ion Transport; D007700:Kinetics; D008055:Lipids / Q000097:blood*; D008094:Lithium / Q000097:blood; D008297:Male; D008875:Middle Aged; D012964:Sodium / Q000097:blood*
D017920:Antiporters; D002352:Carrier Proteins; D000960:Hypolipidemic Agents; D008055:Lipids; C045885:sodium-lithium countertransporter; D008094:Lithium; D012964:Sodium